Polaryx Therapeutics (PLYX) Stock Price, News & Analysis
Company Description
Polaryx Therapeutics (NASDAQ: PLYX) is a publicly traded biotechnology company in the Pharmaceutical Preparations sector. The company has a market capitalization of $112.7M, ranking #5,162 among all listed U.S. companies by market cap.
PLYX stock has declined 93.4% over the past year, placing it at #4,424 in year-to-date performance among tracked companies. Shares last traded at $2.32.
On a trailing twelve-month basis, Polaryx Therapeutics reported net income of -$9.0M and diluted earnings per share of $-0.20.
This page provides a comprehensive overview of PLYX stock, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Polaryx Therapeutics (PLYX) stock last traded at $2.32, up 3.10% from the previous close. Over the past 12 months, the stock has lost 93.4%. At a market capitalization of $112.7M, PLYX is classified as a micro-cap stock with approximately 47.3M shares outstanding.
PLYX Rankings
Latest News
Polaryx Therapeutics has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include private placement, clinical trial. View all PLYX news →
SEC Filings
Polaryx Therapeutics has filed 5 recent SEC filings, including 3 Form 8-K, 1 Form 4, 1 Form 10-Q. The most recent filing was submitted on July 21, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PLYX SEC filings →
Insider Radar
Insider buying activity at Polaryx Therapeutics over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
operating income reached -$7.8M, and net income was -$9.0M. Diluted earnings per share stood at $-0.20. The company generated -$3.9M in operating cash flow. With a current ratio of 8.55, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Polaryx Therapeutics (PLYX) currently stands at 408.5 thousand shares, down 7.5% from the previous reporting period, representing 0.9% of the float. Over the past 12 months, short interest has increased by 1460.7%. This relatively low short interest suggests limited bearish sentiment.
Days to Cover History
Days to cover for Polaryx Therapeutics (PLYX) currently stands at 3.8 days, up 86.3% from the previous period. This days-to-cover ratio represents a balanced liquidity scenario for short positions. The days to cover has increased 282% over the past year, indicating either rising short interest or declining trading volume. The ratio has shown significant volatility over the period, ranging from 1.0 to 3.8 days.
PLYX Company Profile & Sector Positioning
Polaryx Therapeutics (PLYX) operates in the Biotechnology industry within the broader Pharmaceutical Preparations sector and is listed on the NASDAQ. In monthly performance, the stock ranks #3,892 among all tracked companies.